SCHEMBL893644

SCHEMBL893644

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(F)(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 2/20 0.57
FAAH O00519 2/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 2/20 0.56
BLM P54132 2/20 0.56
PLA2G4B P0C869 1/20 0.56
MGLL Q99685 1/20 0.56
PLA2G4C Q9UP65 1/20 0.56
TRPV1 Q8NER1 1/20 0.53
PPARG P37231 3/20 0.48
FFAR1 O14842 2/20 0.48
PPARD Q03181 2/20 0.48
PPARA Q07869 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
CYP3A4 P08684 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL893646 1.00 PLA2G4A (0.57) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL5324851 0.96 PLA2G4A (0.62) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL28417663 0.91 FAAH (0.53) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL24938544 0.91 FAAH (0.53) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL1428312 0.85 FAAH (0.41) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL1818263 0.85 FAAH (0.50) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL1818265 0.85 FAAH (0.50) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL1428313 0.82 FAAH (0.47) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL1428310 0.82 FAAH (0.47) PLA2G4AFAAHALDH1A1MAPTBLM
SCHEMBL19572670 0.82 TRPV1 (0.73) FAAHALDH1A1MAPTBLMTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2665739-A1 METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS THE UNIVERSITY OF ROCHESTER (US) 2013-11-27 EP claimed
WO-2012100248-A1 METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS THE UNIVERSITY OF ROCHESTER (US) 2012-07-26 WO claimed
US-20120114670-A1 METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS UNIVERSITY OF ROCHESTER (US) 2012-05-10 US claimed
US-20120082659-A1 Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-04-05 US claimed
US-20100285001-A1 Method and Compositions Related to Synergistic Responses to Oncogenic Mutations UNIVERSITY OF ROCHESTER (US) 2010-11-11 US claimed
EP-2188630-A2 METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS THE UNIVERSITY OF ROCHESTER (US) 2010-05-26 EP claimed
WO-2009045443-A2 METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS THE UNIVERSITY OF ROCHESTER (US) 2009-04-09 WO claimed
US-20250078957-A1 Unsupervised Machine Learning Methods AMPEL BIOSOLUTIONS LLC (US) 2025-03-06 US disclosed
US-20250022541-A1 Unsupervised Machine Learning Methods AMPEL BIOSOLUTIONS LLC (US) 2025-01-16 US disclosed
US-20240428948-A1 Unsupervised Machine Learning Methods AMPEL BIOSOLUTIONS LLC (US) 2024-12-26 US disclosed
EP-4479973-A1 UNSUPERVISED MACHINE LEARNING METHODS Ampel Biosolutions, LLC (US) 2024-12-25 EP disclosed
WO-2023158713-A1 UNSUPERVISED MACHINE LEARNING METHODS AMPEL BIOSOLUTIONS, LLC (US) 2023-08-24 WO disclosed
US-10870885-B2 Dendritic cell response gene expression, compositions of matters and methods of use thereof THE BROAD INSTITUTE, INC. (US) 2020-12-22 US disclosed
US-20020091153-A1 Novel anandamide amidase inhibitors as analgesic agents NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2002-07-11 US disclosed
US-6391909-B1 AMIDASE INHIBITOR UNIVERSITY OF CONNECTICUT 2002-05-21 US disclosed
EP-1021406-A1 NOVEL ANANDAMIDE AMIDASE INHIBITORS AS ANALGESIC AGENTS THE UNIVERSITY OF CONNECTICUT (US) 2000-07-26 EP disclosed
US-5874459-A Anandamide amidase inhibitors as analgesic agents UNIVERSITY OF CONNECTICUT (US) 1999-02-23 US disclosed
WO-1997045407-A1 NOVEL ANANDAMIDE AMIDASE INHIBITORS AS ANALGESIC AGENTS UNIVERSITY OF CONNECTICUT (US) 1997-12-04 WO disclosed
US-5688825-A Anandamide amidase inhibitors as analgesic agents UNIVERSITY OF CONNECTICUT (US) 1997-11-18 US disclosed
WO-1996040982-A1 THERAPEUTIC INHIBITION OF PHOSPHOLIPASE A2 IN NEURODEGENERATIVE DISEASE ATHENA NEUROSCIENCES, INC. (US) 1996-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091153-A1 Novel anandamide amidase inhibitors as analgesic agents FAAH2, FAAH, NAAA PLA2G4A 153/4885FAAH 2/4885ALDH1A1 2934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.